Fig. 1: WM-3835 inhibits primary CRPC cell viability, cell cycle progression, proliferation and migration in vitro. | Cell Death & Disease

Fig. 1: WM-3835 inhibits primary CRPC cell viability, cell cycle progression, proliferation and migration in vitro.

From: A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo

Fig. 1: WM-3835 inhibits primary CRPC cell viability, cell cycle progression, proliferation and migration in vitro.The alternative text for this image may have been generated using AI.

The primary human prostate cancer cells derived from a CRPC patient, “pPC-1”, were treated with WM-3835 (at designated concentrations) or vehicle control (“Veh”) for designated hours, cell viability (CCK-8 assay, A), colony formation (B), cell death (by testing medium LDH releasing, C) and proliferation (by testing EdU incorporation, D and E), as well as cell cycle distribution (F) and in vitro cell migration (G) were tested. The primary human prostate cancer cells derived from three other CRPC patients, “pPC-2/pPC-3/pPC-4” (H–J), or the primary human prostate epithelial cells (“pEpi1” and “pEpi2”, derived from two patients) (K) were treated WM-3835 (10 μM) or vehicle control (“Veh”) for designated hours, cell viability (H, K), proliferation (I), and migration (J) were examined similarly. Data were expressed as the mean ± standard deviation (SD, n = 5). *P < 0.05 versus “Veh” group. “n. s.” stands for non-statistical difference (P > 0.05). Scale bar = 100 μm.

Back to article page